Pre-eclampsia – a condition that strikes 5% of pregnancies and kills over 60,000 women and hundreds of thousands of babies every year – was once so mysterious that doctors dubbed it the “disease of theories�. Now, a team of researchers says that a single gene could explain most cases.
If their work in mice pans out for human childbirth, could be diagnosed earlier and even prevented by giving expecting mums a naturally occurring breakdown product, says , a researcher at Beth Isreal Deaconess Medical Center in Boston, who led the study.
His team showed that mice without a gene that makes a compound broken-down from oestrogen called 2-methoxyestradiol (2-ME) develop many of the signs of pre-eclampsia, including pre-term birth, high blood pressure and problems forming blood vessels.
Advertisement
“The difference sets the ball rolling and a million other things downstream go wrong,� Kalluri says.
Medical mystery
A major cause of premature deliveries, pre-eclampsia strikes suddenly and often severely. After 20 weeks or longer, women develop high blood pressure and high levels of protein in their urine – a sign of kidney failure. Currently the only way to treat the disease is to deliver the child – often weeks early.
Previous studies pointed to abnormal blood vessel growth that starves a developing placenta of oxygen, but researchers had little clue what set off those changes.
“Nobody really knows what cause pre-eclampsia,� says Kalluri “It has been one of the biggest mysteries in medicine.�
Kalluri’s team noticed that mice missing a gene that makes 2-ME had one of the hallmarks of pre-eclampsia – protein in their urine. The mutant mice also showed elevated levels of two blood vessel proteins that have turned up in pre-eclampsia patients.
Giving the pregnant rodents an extra dose of 2-ME reversed many of the symptoms.
His team also found that 13 women who had suffered from pre-eclampsia had slightly lower levels of 2-ME in their blood before birth than women who went through a normal pregnancy.
‘Always present’
If researchers verify 2-ME’s role in pre-eclampsia in humans, the metabolite could help predict and treat the disease, Kalluri says.
“The wonderful thing about this metabolite is that it is always present in high levels� during pregnancy, he says. “It’s not like we are giving anything that the baby and the mother are not exposed to.�
To strengthen the case, Kalluri’s team plans to study pregnant women with mutations that hamper cells from making 2-ME.
“In some patients with pre-eclampsia, this may well be important,� says James Roberts, a researcher at the University of Pittsburgh. However, one gene alone is unlikely to cause all of the cases, he says.
Treatments may be also premature, says , an epidemiologist and pre-eclampsia expert at the National Institute of Child Health and Human Development in Bethesda, Maryland.
“It is a provocative and potentially important paper – if it is confirmed by other labs,� he says.
Journal reference: (DOI: 10.1038/nature06951)